Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alloreactive NK Cells for AML Consolidation
NCT03955848Unknown
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Open-label trial of alloreactive NK cells in acute myeloid leukemia (AML) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Relapse Free Survival at 36 months and Overall Survival at 36 months. Status: unknown.
02
Drugs
alloreactive NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03955848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955848.